Table 1 Relationship of TRIM36 expression and clinicopathologic characteristics of patients

From: TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways

Variable

TRIM36 expression

 

Negative (nā€‰=ā€‰31)

Positive (nā€‰=ā€‰64)

P value

Age

  

0.605

ā€ƒ<60

3

3

 

ā€ƒ60ā€“70

14

28

 

ā€ƒ>70

14

33

 

Preoperative PSA (ng/ml)

  

0.649

ā€ƒ<10

7

20

 

ā€ƒ10ā€“20

10

20

 

ā€ƒ>20

14

24

 

Gleason score

  

0.005

ā€ƒā‰¦6 or =3+4

12

44

 

ā€ƒ=4+3 or ā‰§8

19

20

 

T stage

  

0.950

ā€ƒpT2

26

54

 

ā€ƒpT3/ T4

5

10

 

Biochemical recurrence

  

0.001

ā€ƒNegative

12

48

 

ā€ƒPositive

19

16

 
  1. Bold values signify Pā€‰<ā€‰0.05. P values were two-tailed and based on the Pearson chi-square test
Back to article page